NYSE:TARO - Taro Pharmaceutical Industries Stock Price, Forecast & News

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced its quarterly earnings data on Monday, February, 3rd. The company reported $1.76 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.54 by $0.22. The business had revenue of $147.68 million for the quarter, compared to analyst estimates of $172 million. Taro Pharmaceutical Industries had a net margin of 38.24% and a return on equity of 12.45%. View Taro Pharmaceutical Industries' Earnings History.

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, May 27th 2020. View Earnings Estimates for Taro Pharmaceutical Industries.

1 analysts have issued 1 year target prices for Taro Pharmaceutical Industries' stock. Their forecasts range from $94.00 to $94.00. On average, they anticipate Taro Pharmaceutical Industries' stock price to reach $94.00 in the next twelve months. This suggests a possible upside of 28.6% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries.

Media stories about TARO stock have been trending extremely negative on Wednesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Taro Pharmaceutical Industries earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Taro Pharmaceutical Industries.

Taro Pharmaceutical Industries saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 154,900 shares, a decrease of 5.1% from the January 15th total of 163,200 shares. Based on an average trading volume of 77,100 shares, the short-interest ratio is currently 2.0 days. Approximately 1.7% of the company's stock are sold short. View Taro Pharmaceutical Industries' Current Options Chain.

Some companies that are related to Taro Pharmaceutical Industries include Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Catalent (CTLT), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP) and Amarin (AMRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Broadcom (AVGO), Skyworks Solutions (SWKS), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Pfizer (PFE), Supernus Pharmaceuticals (SUPN), GW Pharmaceuticals PLC- (GWPH), Jazz Pharmaceuticals (JAZZ) and Neurocrine Biosciences (NBIX).

Taro Pharmaceutical Industries' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (1.89%), Renaissance Technologies LLC (1.61%), Krensavage Asset Management LLC (0.89%), Acadian Asset Management LLC (0.86%), CLARET ASSET MANAGEMENT Corp (0.22%) and Brandes Investment Partners LP (0.21%).

TARO stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Sei Investments Co., Geode Capital Management LLC, Oxford Asset Management LLP, California Public Employees Retirement System, Freestone Capital Holdings LLC, CLARET ASSET MANAGEMENT Corp and Acadian Asset Management LLC.

TARO stock was acquired by a variety of institutional investors in the last quarter, including Krensavage Asset Management LLC, Renaissance Technologies LLC, Brandes Investment Partners LP, Jane Street Group LLC, Hotchkis & Wiley Capital Management LLC, Bank of New York Mellon Corp, Algert Global LLC and Group One Trading L.P..

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TARO stock can currently be purchased for approximately $73.08.

Taro Pharmaceutical Industries has a market capitalization of $2.80 billion and generates $669.89 million in revenue each year. The company earns $281.78 million in net income (profit) each year or $7.23 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.View Additional Information About Taro Pharmaceutical Industries.

The official website for Taro Pharmaceutical Industries is http://www.taro.com/.

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]